The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Biallelic Variants in UBA5 Link Dysfunctional UFM1 Ubiquitin-like Modifier Pathway to Severe Infantile-Onset Encephalopathy
Open accessAbstract
The ubiquitin fold modifier 1 (UFM1) cascade is a recently identified evolutionarily conserved ubiquitin-like modification system whose function and link to human disease have remained largely uncharacterized. By using exome sequencing in Finnish individuals with severe epileptic syndromes, we identified pathogenic compound heterozygous variants in UBA5, encoding an activating enzyme for UFM1, in two unrelated families. Two additional individuals with biallelic UBA5 variants were identified from the UK-based Deciphering Developmental Disorders study and one from the Northern Finland Intellectual Disability cohort. The affected individuals (n = 9) presented in early infancy with severe irritability, followed by dystonia and stagnation of development. Furthermore, the majority of individuals display postnatal microcephaly and epilepsy and develop spasticity. The affected individuals were compound heterozygous for a missense substitution, c.1111G>A (p.Ala371Thr; allele frequency of 0.28% in Europeans), and a nonsense variant or c.164G>A that encodes an amino acid substitution p.Arg55His, but also affects splicing by facilitating exon 2 skipping, thus also being in effect a loss-of-function allele. Using an in vitro thioester formation assay and cellular analyses, we show that the p.Ala371Thr variant is hypomorphic with attenuated ability to transfer the activated UFM1 to UFC1. Finally, we show that the CNS-specific knockout of Ufm1 in mice causes neonatal death accompanied by microcephaly and apoptosis in specific neurons, further suggesting that the UFM1 system is essential for CNS development and function. Taken together, our data imply that the combination of a hypomorphic p.Ala371Thr variant in trans with a loss-of-function allele in UBA5 underlies a severe infantile-onset encephalopathy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R. E., Garimella, K. V., Maguire, J., Hartl, C., Philippakis, A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,457
Analysis of protein-coding genetic variation in 60,706 humans
Exome Aggregation Consortium, Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., et al. (2016) · Nature · doi:10.1038/nature19057 · Cited by 9,587
Self-citationAn integrated map of genetic variation from 1,092 human genomes
The 1000 Genomes Project Consortium (2012) · Nature · doi:10.1038/nature11632 · Cited by 7,711
Self-citationVan der Auwera, G. A., Carneiro, M. O., Hartl, C., Poplin, R., del Angel, G., Levy‐Moonshine, A., Jordan, T., Shakir, K., Roazen, D., Thibault, J., et al. (2013) · Current Protocols in Bioinformatics · doi:10.1002/0471250953.bi1110s43 · Cited by 6,687
Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety
Tronche, F., Kellendonk, C., Kretz, O., Gass, P., Anlag, K., Orban, P. C., Bock, R., Klein, R., & Schütz, G. (1999) · Nature Genetics · doi:10.1038/12703 · Cited by 1,841
Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor
McLaren, W. M., Yates, B., Ríos, D., Chen, Y., Flicek, P., & Cunningham, F. M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq330 · Cited by 1,586
GeneMatcher: a matching tool for connecting investigators with an interest in the same gene.
Sobreira, N., Schiettecatte, F., Valle, D., & Hamosh, A. (2015) · Human Mutation · doi:10.1002/humu.22844 · Cited by 1,529
Large-scale discovery of novel genetic causes of developmental disorders
Study, T. D. D. D. (2015) · Nature · doi:10.1038/nature14135 · Cited by 1,124
Cited by
Sorted by citations
Ribosomal protein RPL26 is the principal target of UFMylation
Walczak, C. P., Leto, D. E., Zhang, L., Riepe, C., Muller, R. Y., DaRosa, P. A., Ingolia, N. T., Elias, J. E., & Kopito, R. R. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1816202116 · Cited by 210
Wang, L., Xu, Y., Rogers, H. M., Saidi, L. F., Noguchi, C. T., Li, H., Yewdell, J. W., Guydosh, N. R., & Ye, Y. (2019) · Cell Research · doi:10.1038/s41422-019-0236-6 · Cited by 184
NGS Technologies as a Turning Point in Rare Disease Research , Diagnosis and Treatment
Marmiesse, A. F., Gouveia, S., & Couce, M. L. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170718101946 · Cited by 188
The UFMylation System in Proteostasis and Beyond
Gerakis, Y., Quintero, M. K., Li, H., & Hetz, C. A. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.09.005 · Cited by 165
PKM1 Confers Metabolic Advantages and Promotes Cell-Autonomous Tumor Cell Growth
Morita, M., Sato, T., Nomura, M., Sakamoto, Y., Inoue, Y., Tanaka, R., Ito, S., Kurosawa, K., Yamaguchi, K., Sugiura, Y., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.004 · Cited by 170
Self-citation
Metadata
- Authors
- Muona, M., Ishimura, R., Laari, A., Ichimura, Y., Linnankivi, T., Keski-Filppula, R., Herva, R., Rantala, H., Paetau, A., Pöyhönen, M., Obata, M., Uemura, T., Karhu, T., Bizen, N., Takebayashi, H., McKee, S., Parker, M. J., Akawi, N., McRae, J., Hurles, M. E., Kuismin, O., Kurki, M. I., Anttonen, A.-K., Tanaka, K., Palotie, A., Waguri, S., Lehesjoki, A.-E., & Komatsu, M.
- Affiliations
- University of Helsinki (FI)
- Tokyo Metropolitan Institute of Medical Science (JP)
- Niigata University (JP)
- Oulu University Hospital (FI)
- Fukushima Medical University (JP)
- Belfast City Hospital (GB)
- Sheffield Children's NHS Foundation Trust (GB)
- Wellcome Sanger Institute (GB)
- Broad Institute (US)
- Corresponding author
- Lehesjoki, Anna-Elina
- Komatsu, Masaaki
- ORCID
- Muona, Mikko
- Ishimura, Ryosuke
- Laari, Anni
- Ichimura, Yoshinobu
- Linnankivi, Tarja
- Rantala, Heikki
- Pöyhönen, Minna
- Uemura, Takefumi
- Bizen, Norihisa
- Takebayashi, Hirohide
- McKee, Shane
- Parker, Michael J.
- Akawi, Nadia
- McRae, Jeremy
- Hurles, Matthew E.
- Kuismin, Outi
- Kurki, Mitja I.
- Anttonen, Anna-Kaisa
- Tanaka, Keiji
- Palotie, Aarno
- Waguri, Satoshi
- Lehesjoki, Anna-Elina
- Komatsu, Masaaki
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 99
- Issue
- 3
- Pages
- 683-694
- ISSN
- 0002-9297 (ISSN-L)
- PMC
- PMC5010641
- OpenAlex
- W2512264989
- Cited by
- 119
- References
- 33
- Citations by year
- 2026: 16 · 2025: 18 · 2024: 13 · 2023: 21 · 2022: 8 · 2021: 9 · 2020: 8 · 2019: 11 · 2018: 10 · 2017: 4 · 2016: 1
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- The American Journal of Human Genetics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Työväentutkimus Vuosikirja (submittedVersion, other-oa)
- Funders
- Japan Society for the Promotion of Science (16J07037)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- UBA5, UFM1, compound heterozygosity, biallelic variants, epilepsy, microcephaly, dystonia, spasticity, exon skipping, hypomorphic variants, loss-of-function alleles, UFC1, thioester formation, central nervous system development, neuronal apoptosis, Finnish patients
- MeSH terms
- Alleles, Animals, Animals, Newborn, Brain Diseases, Central Nervous System, Epilepsy, Exons, Fibroblasts, Finland, Gene Frequency, Heterozygote, Humans, Infant, Intellectual Disability, Microcephaly, Mutation, Neurons, Proteins, Spasms, Infantile, Cohort Studies, Apoptosis, Mice, Knockout, Ubiquitin, Ubiquitin-Activating Enzymes, Mice, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
